MX2021011589A - Composición anestésica y método para anestesiar el ojo. - Google Patents

Composición anestésica y método para anestesiar el ojo.

Info

Publication number
MX2021011589A
MX2021011589A MX2021011589A MX2021011589A MX2021011589A MX 2021011589 A MX2021011589 A MX 2021011589A MX 2021011589 A MX2021011589 A MX 2021011589A MX 2021011589 A MX2021011589 A MX 2021011589A MX 2021011589 A MX2021011589 A MX 2021011589A
Authority
MX
Mexico
Prior art keywords
articaine
eye
anesthetic
formulation
amount
Prior art date
Application number
MX2021011589A
Other languages
English (en)
Inventor
Martin Uram
Original Assignee
Martin Uram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/024239 external-priority patent/WO2019191200A1/en
Application filed by Martin Uram filed Critical Martin Uram
Publication of MX2021011589A publication Critical patent/MX2021011589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición anestésica tópica oftálmica incluye una formulación con una cantidad de articaína para proporcionar propiedades anestésicas cuando se aplica tópicamente al ojo, y un pH, viscosidad, osmolalidad, constante de disociación y aditivos como antioxidantes, amortiguadores, metilcelulosa, para lograr eficacia y seguridad. La composición puede contener articaína en cantidades de aproximadamente 4.0 % p/v a aproximadamente 12.0% p/v y tener un pH de aproximadamente pH 3.5 a pH 7.0. El amortiguador puede ser un complejo de borato/manitol obtenido a partir de ácido bórico o su sal y D manitol. Las formulaciones de articaína pueden lograr una anestesia adecuada del aspecto interno de la pared del ojo mediante la aplicación tópica, sin necesidad de utilizar un anestésico inyectable. Las implementaciones ejemplares de la divulgación incluyen formulaciones que incluyen articaína en una cantidad de al menos 7.0 % p/v, donde la formulación es una solución acuosa, un gel, una pomada o en una forma encapsulada.
MX2021011589A 2019-03-26 2020-03-16 Composición anestésica y método para anestesiar el ojo. MX2021011589A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962824207P 2019-03-26 2019-03-26
PCT/US2019/024239 WO2019191200A1 (en) 2018-03-27 2019-03-27 Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
US16/811,798 US11096922B2 (en) 2018-03-27 2020-03-06 Anesthetic composition and method of anesthetizing the eye
PCT/US2020/022915 WO2020197816A1 (en) 2019-03-26 2020-03-16 Anesthetic composition and method of anesthetizing the eye

Publications (1)

Publication Number Publication Date
MX2021011589A true MX2021011589A (es) 2021-12-15

Family

ID=72609654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011589A MX2021011589A (es) 2019-03-26 2020-03-16 Composición anestésica y método para anestesiar el ojo.

Country Status (11)

Country Link
EP (1) EP3946311A4 (es)
JP (1) JP2022527621A (es)
KR (1) KR20210143254A (es)
CN (1) CN114072139A (es)
AU (1) AU2020245203A1 (es)
BR (1) BR112021019039A2 (es)
CA (1) CA3134531A1 (es)
IL (1) IL286624A (es)
MX (1) MX2021011589A (es)
SG (1) SG11202110423UA (es)
WO (1) WO2020197816A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
ATE547122T1 (de) * 2001-11-21 2012-03-15 Novartis Pharma Gmbh Zusammensetzung zur stabilisierung von hyaluronsäure
CN101695488B (zh) * 2009-11-05 2012-05-02 蚌埠丰原涂山制药有限公司 复方阿替卡因注射用冻干制剂及其制备方法
CN101721407B (zh) * 2009-11-23 2013-04-10 蚌埠丰原涂山制药有限公司 复方盐酸阿替卡因注射液及其制备方法
FR2968996B1 (fr) * 2010-12-17 2013-04-12 Anteis Sa Formulation aqueuse injectable sterile utilisee en ophtalmologie
FR3036035B1 (fr) * 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
JP2018526423A (ja) * 2015-09-08 2018-09-13 ビューポイント セラピューティクス， インコーポレイテッド 眼科疾患を処置するための化合物および製剤
WO2018220283A1 (fr) * 2017-05-29 2018-12-06 Kh Medtech Sarl Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine

Also Published As

Publication number Publication date
IL286624A (en) 2021-10-31
JP2022527621A (ja) 2022-06-02
AU2020245203A1 (en) 2021-11-11
BR112021019039A2 (pt) 2021-11-30
EP3946311A1 (en) 2022-02-09
WO2020197816A1 (en) 2020-10-01
KR20210143254A (ko) 2021-11-26
SG11202110423UA (en) 2021-10-28
EP3946311A4 (en) 2022-12-28
CN114072139A (zh) 2022-02-18
CA3134531A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
EA025026B1 (ru) Система подачи невязкого полимерного раствора на основе простагландина, не содержащего консервант
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
RU2010142353A (ru) Водные фармацевтические композиции, содержащие борат-полиольные комплексы
PH12015502542A1 (en) Stabilized pemetrexed formulation
EA202091755A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
KR20180110113A (ko) 도르졸라미드와 브리모니딘을 포함하는 의약 조성물
MX2023009052A (es) Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo.
MX2021011589A (es) Composición anestésica y método para anestesiar el ojo.
BR112015006464A2 (pt) composição farmacêutica compreendendo rebamipida
TW201309306A (zh) 含有玻尿酸或其鹽及丙二醇之點眼液
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
MX2020013457A (es) Emulsiones estabilizadas con agentes acidos.
TWI604858B (zh) 含有２－胺基－３－（４－溴苯甲醯基）苯基醋酸之水性組成物及其製造方法
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
CN102215819B (zh) 具有相对低的离子强度的药物组合物
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
RU2014101995A (ru) Антипаразитарная композиция, содержащая макроциклический лактон и левамизол, и способ лечения паразитарной инфестации
JP2017165729A (ja) メグルミン又はその塩からなる防腐剤
BR112014013564A8 (pt) composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz
WO2015046281A1 (ja) 安定化された２－アミノ－３－（４－ブロモベンゾイル）フェニル酢酸含有水性組成物
PL434409A1 (pl) Zastosowanie kompozycji alkaloidów protoberberynowych jako środka antybakteryjnego i antygrzybicznego do stabilizacji kolagenu rybiego oraz sposób stabilizacji kolagenu rybiego
PH12016500932B1 (en) Method of treating ocular disorders
WO2017041202A1 (zh) 一种具有防腐功效的组合物及其制备方法和应用